NOVYY REZhIM PERVOY LINII KhIMIOTERAPII METASTATIChESKOGO KOLOREKTAL'NOGO RAKA
- Authors: Darenskaya A.D1, Dobrova N.V1
-
Affiliations:
- Issue: No 8 (2014)
- Pages: 57-61
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286936
- ID: 286936
Cite item
Abstract
The article presents the intermediate results of the evaluation of newly developed regimen of 1st line chemotherapy of metastatic colorectal cancer, including oxaliplati, irinotecan, and 5-fluorouracil in the weekly and extended mode ± panitumumab. This mode of chemotherapy has demonstrated high efficacy and low toxicity. Objective tumor response to the treatment was registered in 100 % of cases. A clinical case of the application of the three-component chemotherapy regimen for the achievement of complete tumor regression in a patient with metastatic colorectal cancer is demonstrated.
Full Text
About the authors
A. D Darenskaya
Email: darenskaya@bk.ru
N. V Dobrova
Email: dobrova2008@rambler.ru
References
- Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
- Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.
- Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007; 25(13): 1670-76.
- Masi G., Vasile E., Loupakis F., et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J. Natl. Cancer Inst. 2011; 103(1): 21-30.
- Peinert S., Grothe W., Stein A., et al. Safety and efficacy of weekly 5-fluorouracil/folinic acid/ oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Ther. Adv. Med. Oncol. 2010; 2 (3): 161-74.
- Vasile E., Masi G., Fornaro L., et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer. 2009; 100(11): 1720-24.
- Bajetta E., Celio L., Ferrario E., et al. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2007; 18(11): 1810-16.